English
Insider transactions
EDGARPROMIS NEUROSCIENCES INC.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-21.
- Open-market purchases (code P)
- 11 transactions, 752,466 shares
- Sum of shares × price per share: 8,876,603.32
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–37 of 37
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-04 Filed 2026-11-06 | Williams Eugene Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 26,500 | 3.43 | 90,895Derived: shares × price per share. Exact value 90895.00. | 40,213 | Direct (D) | No | — | Open filing 0001374339-26-000011 Read from the filing’s XML Dispute this row |
| 2026-11-02 Filed 2026-11-03 | Cashman Neil Director · Officer: Chief Scientific Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 10,000 | 3.86 | 38,600Derived: shares × price per share. Exact value 38600.00. | 14,532 | Direct (D) | No | — | Open filing 0001374339-26-000009 Read from the filing’s XML Dispute this row |
| 2026-10-30 Filed 2026-11-03 | Williams Eugene Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,316 | 3.99 | 5,250.84Derived: shares × price per share. Exact value 5250.84. | 13,713 | Direct (D) | No | — | Open filing 0001374339-26-000010 Read from the filing’s XML Dispute this row |
| 2026-10-05 Filed 2026-10-06 | Rubino Ivana Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 80,000 | 0 | — | 80,000 | Direct (D) | No | F1
| Open filing 0001104659-26-114106 Read from the filing’s XML Dispute this row |
| 2026-08-05 Filed 2026-08-07 | Kaplan Johanne Officer: Chief Development Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,280 | 13.3 | 30,324Derived: shares × price per share. Exact value 30324.0. | 6,221 | Direct (D) | No | — | Open filing 0001104659-26-092673 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Milbury Max A. Officer: Principal Accounting Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 18,167 | 0 | — | 18,167 | Direct (D) | No | F1
| Open filing 0001104659-26-065766 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Shafmaster Madge K. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,500 | 0 | — | 5,500 | Direct (D) | No | F1
| Open filing 0001104659-26-065771 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Shafmaster Madge K. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,000 | 0 | — | 11,000 | Direct (D) | No | F2
| Open filing 0001104659-26-065771 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Warma Neil K Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 160,000 | 0 | — | 160,000 | Direct (D) | No | F1
| Open filing 0001104659-26-065772 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Kaplan Johanne Officer: Chief Development Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 50,000 | Direct (D) | No | F1
| Open filing 0001104659-26-065762 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Williams Eugene Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,500 | 0 | — | 5,500 | Direct (D) | No | F1
| Open filing 0001104659-26-065774 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Williams Eugene Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,000 | 0 | — | 11,000 | Direct (D) | No | F2
| Open filing 0001104659-26-065774 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Alex Slanix Paul Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,500 | 0 | — | 5,500 | Direct (D) | No | F1
| Open filing 0001104659-26-065755 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Alex Slanix Paul Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,000 | 0 | — | 11,000 | Direct (D) | No | F2
| Open filing 0001104659-26-065755 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Mandel-Brehm Josh Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,500 | 0 | — | 5,500 | Direct (D) | No | F1
| Open filing 0001104659-26-065763 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Mandel-Brehm Josh Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,000 | 0 | — | 11,000 | Direct (D) | No | F2
| Open filing 0001104659-26-065763 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | WYMAN WILLIAM W Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 5,500 | 0 | — | 5,500 | Direct (D) | No | F1
| Open filing 0001104659-26-065775 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | WYMAN WILLIAM W Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 11,000 | 0 | — | 11,000 | Direct (D) | No | F2
| Open filing 0001104659-26-065775 Read from the filing’s XML Dispute this row |
| 2026-05-20 Filed 2026-05-22 | Cashman Neil Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 50,000 | 0 | — | 50,000 | Direct (D) | No | F1
| Open filing 0001104659-26-065769 Read from the filing’s XML Dispute this row |
| 2026-04-22 Filed 2026-04-23 | Kirwin Patrick D. Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 4,000 | 11.33 | 45,320Derived: shares × price per share. Exact value 45320.00. | 4,653 | Indirect (I) By Patrick D. Kirwin Professional Corp | No | — | Open filing 0001104659-26-047977 Read from the filing’s XML Dispute this row |
| 2026-03-05 Filed 2026-03-06 | Williams Eugene Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,000 | 24.4 | 48,800Derived: shares × price per share. Exact value 48800.0. | 12,397 | Direct (D) | No | — | Open filing 0001374339-26-000004 Read from the filing’s XML Dispute this row |
| 2026-03-04 Filed 2026-03-04 | Williams Eugene Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,000 | 24 | 48,000Derived: shares × price per share. Exact value 48000. | 10,397 | Direct (D) | No | — | Open filing 0001374339-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-03 Filed 2026-03-04 | Williams Eugene Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,000 | 21.89 | 21,890Derived: shares × price per share. Exact value 21890.00. | 8,397 | Direct (D) | No | — | Open filing 0001374339-26-000003 Read from the filing’s XML Dispute this row |
| 2026-03-02 Filed 2026-03-04 | Williams Eugene Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,000 | 22.53 | 22,530Derived: shares × price per share. Exact value 22530.00. | 7,397 | Direct (D) | No | — | Open filing 0001374339-26-000003 Read from the filing’s XML Dispute this row |
| 2026-02-19 Filed 2026-02-23 | Kaplan Johanne Officer: Chief Development Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 1,629 | 15.35 | 25,005.15Derived: shares × price per share. Exact value 25005.15. | 3,941 | Direct (D) | No | — | Open filing 0001374339-26-000002 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Warma Neil K Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,183 | 12.13 | 74,999.79Derived: shares × price per share. Exact value 74999.79. | 6,183 | Direct (D) | No | F1
| Open filing 0001104659-26-011138 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Warma Neil K Director · Officer: Chief Executive Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,183 | — | — | 6,183 | Direct (D) | No | F1, F2
| Open filing 0001104659-26-011138 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Milbury Max A. Other: Principal Accounting Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,595 | 12.13 | 79,997.35Derived: shares × price per share. Exact value 79997.35. | 8,409 | Direct (D) | No | F1, F2
| Open filing 0001104659-26-011137 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Milbury Max A. Other: Principal Accounting Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 6,595 | — | — | 6,595 | Direct (D) | No | F1, F3
| Open filing 0001104659-26-011137 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | ABG Management Ltd. 10% ownerAlly Bridge MedAlpha Master Fund L.P. 10% ownerAlly Bridge Group (NY) LLC 10% ownerYu Fan 10% ownerAlex Slanix Paul Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 700,741 | 12.13 | 8,499,988.33Derived: shares × price per share. Exact value 8499988.33. | 943,090 | Indirect (I) See Footnote | No | F1, F2, F3, F4, F5
| Open filing 0001493152-26-005410 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | ABG Management Ltd. 10% ownerAlly Bridge MedAlpha Master Fund L.P. 10% ownerAlly Bridge Group (NY) LLC 10% ownerYu Fan 10% ownerAlex Slanix Paul Director | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 700,741 | — | — | 700,741 | Indirect (I) See Footnote | No | F1, F6, F3, F4, F5, F7
| Open filing 0001493152-26-005410 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Kirwin Patrick D. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,050 | 12.13 | 36,996.5Derived: shares × price per share. Exact value 36996.50. | 5,135 | Direct (D) | No | F1, F2
| Open filing 0001104659-26-011135 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Kirwin Patrick D. Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 3,050 | — | — | 3,050 | Direct (D) | No | F1, F3
| Open filing 0001104659-26-011135 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Cashman Neil Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,122 | 12.13 | 49,999.86Derived: shares × price per share. Exact value 49999.86. | 4,122 | Indirect (I) By Research Capital Corporation | No | F1
| Open filing 0001104659-26-011140 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Cashman Neil Director · Officer: Chief Scientific Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 4,122 | — | — | 4,122 | Indirect (I) By Research Capital Corporation | No | F1, F3
| Open filing 0001104659-26-011140 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Kaplan Johanne Officer: Chief Development Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,060 | 12.13 | 24,987.8Derived: shares × price per share. Exact value 24987.80. | 2,312 | Direct (D) | No | F1, F2
| Open filing 0001104659-26-011139 Read from the filing’s XML Dispute this row |
| 2026-02-03 Filed 2026-02-05 | Kaplan Johanne Officer: Chief Development Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,060 | — | — | 2,060 | Direct (D) | No | F1, F3
| Open filing 0001104659-26-011139 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
Quarter ending 2026-09-30: 8,935 filings read, the latest filed 2026-11-20. Prior quarter ending 2026-06-30: 9,178 filings read.
Showing 1–31 of 31
| Manager | Shares or principal | Value as filed | Change from the prior quarter | Source |
|---|---|---|---|---|
| Janus Henderson Group Ltd. Partly reported under another manager | 1,292,657 SH | 14,089,961 dollars | Not in the prior quarter’s filings read | Open filing 0001085146-26-000952 Filed 2026-11-16 Dispute this row |
| Deep Track Capital, LP | 740,117 SH | 8,030,269 dollars | Lower by 95,538 Prior quarter: 835,655 | Open filing 0001856083-26-000006 Filed 2026-11-16 Dispute this row |
| WELLINGTON MANAGEMENT GROUP LLP Partly reported under another manager | 696,378 SH | 7,555,701 dollars | Unchanged Prior quarter: 696,378 | Open filing 0000902219-26-000323 Filed 2026-11-16 Dispute this row |
| Ally Bridge Group (NY) LLC | 620,319 SH | 6,730,461 dollars | Unchanged Prior quarter: 620,319 | Open filing 0001193125-26-463652 Filed 2026-11-16 Dispute this row |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 564,275 SH | 6,122,384 dollars | Higher by 400,000 Prior quarter: 164,275 | Open filing 0001172661-26-005200 Filed 2026-11-16 Dispute this row |
| Trails Edge Capital Partners, LP | 557,103 SH | 6,044,568 dollars | Unchanged Prior quarter: 557,103 | Open filing 0002077247-26-000005 Filed 2026-11-16 Dispute this row |
| Yu Fan | 329,760 SH | 3,577,896 dollars | Unchanged Prior quarter: 329,760 | Open filing 0001193125-26-463618 Filed 2026-11-16 Dispute this row |
| Woodline Partners LP | 314,601 SH | 3,413,421 dollars | Lower by 127,310 Prior quarter: 441,911 | Open filing 0001172661-26-005063 Filed 2026-11-16 Dispute this row |
| SPHERA FUNDS MANAGEMENT LTD. Partly reported under another manager | 254,782 SH | 2,764,390 dollars | Lower by 70,809 Prior quarter: 325,591 | Open filing 0001496201-26-000006 Filed 2026-11-16 Dispute this row |
| 683 Capital Management, LLC Partly reported under another manager | 250,000 SH | 2,712,500 dollars | Higher by 155,000 Prior quarter: 95,000 | Open filing 0001404574-26-000027 Filed 2026-11-16 Dispute this row |
| Ikarian Capital, LLC | 205,000 SH | 2,224,250 dollars | Unchanged Prior quarter: 205,000 | Open filing 0001420506-26-002881 Filed 2026-11-16 Dispute this row |
| AMERIPRISE FINANCIAL INC Partly reported under another manager | 185,700 SH | 2,014,845 dollars | Unchanged Prior quarter: 185,700 | Open filing 0001193125-26-463125 Filed 2026-11-16 Dispute this row |
| MILLENNIUM MANAGEMENT LLC | 121,123 SH | 1,314,185 dollars | Higher by 65,078 Prior quarter: 56,045 | Open filing 0001273087-26-000011 Filed 2026-11-16 Dispute this row |
| ADAR1 Capital Management, LLC | 92,850 SH | 976,782 dollars | Unchanged Prior quarter: 92,850 | Open filing 0001940272-26-000033 Filed 2026-11-16 Dispute this row |
| BOOTHBAY FUND MANAGEMENT, LLC | 62,078 SH | 673,546 dollars | Unchanged Prior quarter: 62,078 | Open filing 0001549230-26-000012 Filed 2026-11-16 Dispute this row |
| CITADEL ADVISORS LLC Partly reported under another manager | 22,902 SH | 248,487 dollars | Not in the prior quarter’s filings read | Open filing 0001104659-26-128228 Filed 2026-11-16 Dispute this row |
| TWO SIGMA INVESTMENTS, LP | 16,228 SH | 176,074 dollars | Not in the prior quarter’s filings read | Open filing 0000899140-26-001341 Filed 2026-11-16 Dispute this row |
| JANE STREET GROUP, LLC Partly reported under another manager | 14,621 SH | 158,638 dollars | Not in the prior quarter’s filings read | Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row |
| Quadrature Capital Ltd Partly reported under another manager | 11,615 SH | 126,023 dollars | Not in the prior quarter’s filings read | Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row |
| Seven Fleet Capital Management LP | 10,600 SH | 115,010 dollars | Unchanged Prior quarter: 10,600 | Open filing 0001013594-26-001198 Filed 2026-11-16 Dispute this row |
| MORGAN STANLEY Partly reported under another manager | 7,559 SH | 82,015 dollars | Unchanged Prior quarter: 7,559 | Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row |
| OSAIC HOLDINGS, INC. Partly reported under another manager | 360 SH | 3,906 dollars | Unchanged Prior quarter: 360 | Open filing 0001677044-26-000011 Filed 2026-11-12 Dispute this row |
| JPMORGAN CHASE CO Partly reported under another manager | 285 SH | 3,118 dollars | Not in the prior quarter’s filings read | Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row |
| ROYAL BANK OF CANADA Partly reported under another manager | 218 SH | 2,000 dollars | Unchanged Prior quarter: 218 | Open filing 0001140361-26-044123 Filed 2026-11-16 Dispute this row |
| Steward Partners Investment Advisory, LLC | 94 SH | 1,020 dollars | Unchanged Prior quarter: 94 | Open filing 0001723397-26-000006 Filed 2026-11-13 Dispute this row |
| Tower Research Capital LLC (TRC) Partly reported under another manager | 33 SH | 358 dollars | Not in the prior quarter’s filings read | Open filing 0001533421-26-000010 Filed 2026-11-16 Dispute this row |
| Federation des caisses Desjardins du Quebec | 10 SH | 108 dollars | Unchanged Prior quarter: 10 | Open filing 0002022297-26-000010 Filed 2026-11-16 Dispute this row |
| Caitong International Asset Management Co., Ltd | 10 SH | 108 dollars | Higher by 7 Prior quarter: 3 | Open filing 0001628280-26-068135 Filed 2026-10-29 Dispute this row |
| TD Waterhouse Canada Inc. Partly reported under another manager | 5 SH | 46 dollars | Unchanged Prior quarter: 5 | Open filing 0002052595-26-000100 Filed 2026-10-16 Dispute this row |
| NATIONAL BANK OF CANADA /FI/ Partly reported under another manager | 2 SH | 22 dollars | Not in the prior quarter’s filings read | Open filing 0000926171-26-000014 Filed 2026-11-16 Dispute this row |
| UBS Group AG Partly reported under another manager | 1 SH | 11 dollars | Lower by 690 Prior quarter: 691 | Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row |
Managers in the prior quarter with no filing read for the latest
They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.
- Jupiter Topco LLC 1,292,757 SH
- Squadron Capital Management LLC 324,977 SH
- GREAT POINT PARTNERS LLC 86,150 SH
- BANK OF MONTREAL /CAN/ 11,371 SH
- Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
- Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
- A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
- A change is the difference between two quarter-end snapshots, not a trade.
- A position reported under another manager may also appear in that manager’s filing; rows are not added together.
- Holdings the securities list cannot place with this company, or places ambiguously, are not shown.
Trades by members of Congress
Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.
No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| Great Point Partners, LLC Common Shares, No Par Value per Share | 6.77 | 650,731.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-005410 Dispute this row |
| Dr. Jeffrey R. Jay, M.D. Common Shares, No Par Value per Share | 6.77 | 650,731.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-005410 Dispute this row |
| Ms. Lillian Nordahl Common Shares, No Par Value per Share | 6.77 | 650,731.00 | 09/30/2026 Filed 2026-11-16 | SCHEDULE 13G/AAmendment 2 | Open filing 0001172661-26-005410 Dispute this row |
| Adage Capital Management, L.P. Common Shares, no par value per share | 7.73 | 703,550.00 | 09/30/2026 Filed 2026-11-12 | SCHEDULE 13G | Open filing 0000919574-26-007569 Dispute this row |
| Robert Atchinson Common Shares, no par value per share | 7.73 | 703,550.00 | 09/30/2026 Filed 2026-11-12 | SCHEDULE 13G | Open filing 0000919574-26-007569 Dispute this row |
| Phillip Gross Common Shares, no par value per share | 7.73 | 703,550.00 | 09/30/2026 Filed 2026-11-12 | SCHEDULE 13G | Open filing 0000919574-26-007569 Dispute this row |
| Great Point Partners, LLC Common Shares, No Par Value per Share | 7.66 | 736,881.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-26-003535 Dispute this row |
| Dr. Jeffrey R. Jay, M.D. Common Shares, No Par Value per Share | 7.66 | 736,881.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-26-003535 Dispute this row |
| Ms. Lillian Nordahl Common Shares, No Par Value per Share | 7.66 | 736,881.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001172661-26-003535 Dispute this row |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. Common Stock | 7.8 | 696,378.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001903360-26-000014 Dispute this row |
| Wellington Management Group LLP Common Stock | 7.8 | 696,378.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0000902219-26-000224 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 7.8 | 696,378.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0000902219-26-000224 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 7.8 | 696,378.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0000902219-26-000224 Dispute this row |
| Wellington Management Company LLP Common Stock | 7.8 | 696,378.00 | 06/30/2026 Filed 2026-08-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0000902219-26-000224 Dispute this row |
| Wellington Management Group LLP Common Stock | 10.0 | 895,871.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000902219-26-000122 Dispute this row |
| Wellington Group Holdings LLP Common Stock | 10.0 | 895,871.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000902219-26-000122 Dispute this row |
| Wellington Investment Advisors Holdings LLP Common Stock | 10.0 | 895,871.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000902219-26-000122 Dispute this row |
| Wellington Management Company LLP Common Stock | 10.0 | 895,871.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0000902219-26-000122 Dispute this row |
| Great Point Partners, LLC Common Shares, No Par Value per Share | 9.99 | 954,082.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0001172661-26-002037 Dispute this row |
| Dr. Jeffrey R. Jay, M.D. Common Shares, No Par Value per Share | 9.99 | 954,082.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0001172661-26-002037 Dispute this row |
| Ms. Lillian Nordahl Common Shares, No Par Value per Share | 9.99 | 954,082.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G | Open filing 0001172661-26-002037 Dispute this row |
| Michael S. Gordon Common Shares, No Par Value | 2.0 | 181,632.00 | 03/31/2026 Filed 2026-05-07 | SCHEDULE 13G/AAmendment 5 | Open filing 0001104659-26-057168 Dispute this row |
| Title 19 Promis Common Shares, No Par Value | 2.0 | 181,632.00 | 03/31/2026 Filed 2026-05-07 | SCHEDULE 13G/AAmendment 5 | Open filing 0001104659-26-057168 Dispute this row |
| JANUS HENDERSON GROUP PLC Common Shares | 14.4 | 1,292,757 | 03/31/2026 Filed 2026-04-07 | SCHEDULE 13G | Open filing 0001274173-26-000104 Dispute this row |
| Wellington Biomedical Innovation Master Investors (Cayman) II, L.P. Common Stock | 9.99 | 895,877.00 | 03/11/2026 Filed 2026-03-18 | SCHEDULE 13G | Open filing 0001903360-26-000013 Dispute this row |
| Trails Edge Capital Partners, LP Common Shares, no par value per share | 9.9 | 933,477.00 | 02/03/2026 Filed 2026-02-10 | SCHEDULE 13G | Open filing 0001493152-26-005965 Dispute this row |
| Trails Edge Biotechnology Master Fund, LP Common Shares, no par value per share | 9.9 | 933,477.00 | 02/03/2026 Filed 2026-02-10 | SCHEDULE 13G | Open filing 0001493152-26-005965 Dispute this row |
| Ortav Yehudai Common Shares, no par value per share | 9.9 | 933,477.00 | 02/03/2026 Filed 2026-02-10 | SCHEDULE 13G | Open filing 0001493152-26-005965 Dispute this row |
| ABG Management Ltd. Common Shares, no par value per share | 6.3 | 572,677.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| Ally Bridge Group (NY) LLC Common Shares, no par value per share | 6.3 | 572,677.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| Ally Bridge MedAlpha Master Fund L.P. Common Shares, no par value per share | 6.3 | 572,677.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| ABG V-SIV IX Limited Common Shares, no par value per share | 7.1 | 659,520.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| Ally Bridge Group Global Life Science Capital Partners V, L.P. Common Shares, no par value per share | 7.1 | 659,520.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| ABG Global Life Science Capital Partners V GP, L.P. Common Shares, no par value per share | 7.1 | 659,520.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| ABG Global Life Science Capital Partners V GP Limited Common Shares, no par value per share | 7.1 | 659,520.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| ABG V-SIV X Limited Common Shares, no par value per share | 4.5 | 412,200.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| Fan Yu Common Shares, no par value per share | 17.0 | 1,644,397.00 | 02/03/2026 Filed 2026-02-05 | SCHEDULE 13D/AAmendment 2 | Open filing 0001493152-26-005412 Dispute this row |
| Deep Track Capital, LP Common Shares, no par value per share | 9.99 | 902,561.00 | 01/30/2026 Filed 2026-02-06 | SCHEDULE 13G | Open filing 0001172661-26-000524 Dispute this row |
| Deep Track Biotechnology Master Fund, Ltd. Common Shares, no par value per share | 7.79 | 703,457.00 | 01/30/2026 Filed 2026-02-06 | SCHEDULE 13G | Open filing 0001172661-26-000524 Dispute this row |
| David Kroin Common Shares, no par value per share | 9.99 | 902,561.00 | 01/30/2026 Filed 2026-02-06 | SCHEDULE 13G | Open filing 0001172661-26-000524 Dispute this row |
| Deep Track Special Opportunities Fund, LP. Common Shares, no par value per share | 2.20 | 199,104.00 | 01/30/2026 Filed 2026-02-06 | SCHEDULE 13G | Open filing 0001172661-26-000524 Dispute this row |
| ABG Management Ltd. Common Shares, no par value per share | 11.3 | 6,070,405.00 | 01/29/2026 Filed 2026-02-02 | SCHEDULE 13D/AAmendment 1 | Open filing 0001493152-26-004760 Dispute this row |
| Ally Bridge Group (NY) LLC Common Shares, no par value per share | 11.3 | 6,070,405.00 | 01/29/2026 Filed 2026-02-02 | SCHEDULE 13D/AAmendment 1 | Open filing 0001493152-26-004760 Dispute this row |
| Ally Bridge MedAlpha Master Fund L.P. Common Shares, no par value per share | 11.3 | 6,070,405.00 | 01/29/2026 Filed 2026-02-02 | SCHEDULE 13D/AAmendment 1 | Open filing 0001493152-26-004760 Dispute this row |
| Fan Yu Common Shares, no par value per share | 11.3 | 6,070,405.00 | 01/29/2026 Filed 2026-02-02 | SCHEDULE 13D/AAmendment 1 | Open filing 0001493152-26-004760 Dispute this row |
| Great Point Partners, LLC Common Shares, no par value per share | 9.99 | 409,648.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 5 | Open filing 0001172661-26-001139 Dispute this row |
| Dr. Jeffrey R. Jay, M.D. Common Shares, no par value per share | 9.99 | 409,648.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 5 | Open filing 0001172661-26-001139 Dispute this row |
| Ms. Lillian Nordahl Common Shares, no par value per share | 9.99 | 409,648.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 5 | Open filing 0001172661-26-001139 Dispute this row |
| Armistice Capital, LLC Common Shares, no par value per share | 0.93 | 504,673.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001172661-26-001223 Dispute this row |
| Steven Boyd Common Shares, no par value per share | 0.93 | 504,673.00 | 12/31/2025 Filed 2026-02-17 | SCHEDULE 13G/AAmendment 4 | Open filing 0001172661-26-001223 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,715,586 filings read, dated 2004-06-14 to 2026-11-20: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 131,968 |
| 2016 | 222,642 |
| 2017 | 222,009 |
| 2018 | 223,345 |
| 2019 | 216,482 |
| 2020 | 226,343 |
| 2021 | 249,835 |
| 2022 | 231,682 |
| 2023 | 229,674 |
| 2024 | 234,045 |
| 2025 | 235,520 |
| 2026 | 263,828 |
Filings made before the SEC required XML are listed, not extracted.